Project Grant F31AI200449
Award Date 12/1/26
Completion Date 6/3/28
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded $453,750 to Massachusetts General Hospital on July 13, 2026, to identify and characterize genes in Borrelia burgdorferi that influence dissemination of Lyme disease in vertebrate hosts. The research focuses on microbial genetic determinants that drive dissemination—the progression from localized infection to severe systemic disease affecting the nervous system, joints, or...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College, doing business as Tufts University School of Medicine, $862,348 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the mechanisms targeting a Borrelia burgdorferi protein CspZ to prevent Lyme disease infection. The project addresses mechanisms by which B. burgdorferi evades complement-mediated immune killing. The recipient has generated a CspZ mutant...
- The National Institute of Allergy and Infectious Diseases awarded the University of Toledo $768,796 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify immunoprotective antigens for preventing Lyme disease caused by Borrelia burgdorferi. The research will evaluate attenuated bacterial mutants as vaccine candidates, building on the recipient's prior identification of a BB strain lacking a chemotaxis-related gene that is rapidly cleared from...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $165,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 1, 2025, with a completion date of June 30, 2027. This award funds the development of an improved transposon mutagenesis system for comprehensive genetic analysis of Borrelia burgdorferi, the causative agent of Lyme disease. The primary deliverables...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $700,997 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune homeostasis during Borrelia burgdorferi infection. The research defines the impact of BB infection-induced changes in gastrointestinal barrier function and microbiota on immune system health. The project tests the hypothesis that BB infection-induced gut barrier dysfunction,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Kansas Medical Center Research Institute $782,462 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of lipoprotein sorting and secretion in Borrelia spirochetes, the causative agents of Lyme disease and relapsing fever. The research examines how Borrelia burgdorferi deploys surface lipoproteins—which cover the bacterium's unique...
- The National Institute of Allergy and Infectious Diseases awarded The University of Kentucky Research Foundation $420,063 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and functionally characterize bacterial and phage proteins that control BB-1 bacteriophage production in Lyme disease spirochetes. The funded research targets the molecular switches governing the transition of BB-1 bacteriophages from dormant plasmid replication to lytic...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $261,675 on July 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on streptothricin derivatization against gram-negative ESKAPE pathogens. The research explores synthetic modification of the gulosamine sugar moiety of streptothricins—antibiotics discovered over 70 years ago that inhibit bacterial protein translation. Preliminary data...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $715,313 on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Borrelia burgdorferi genotypic diversity, pathogenesis, and host cellular responses in Lyme disease. The award funds research on Borrelia burgdorferi outer surface protein C (OspC) genotypes and their association with disease severity and progression, including Lyme neuroborreliosis (LNB)....
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $859,278 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate discovery of narrow-spectrum antibiotics targeting Borrelia burgdorferi, the causative agent of Lyme disease. Narrow-spectrum agents that affect only the target bacterium avoid resistance propagation in off-target bacteria, microbiome...